Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05887882 · ClinicalTrials.gov registry record · Phase 1
Intra-Tumoral Injections of Natural Killer Cells for Recurrent Malignant Pediatric Brain Tumors
A Phase 1 study of Pediatric Brain Tumor and Pediatric Neoplasm, sponsored by Sabine Mueller, MD, PhD.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 8
- Study locations
NCT05887882 is a Phase 1 study of Pediatric Brain Tumor and Pediatric Neoplasm that is actively recruiting participants, run by Sabine Mueller, MD, PhD. The registered enrollment target is 24 participants, below the 42-participant average among 9 other Pediatric Brain Tumor trials with a reported enrollment target (43% lower). The trial reports 8 study locations across 8 states.
The verdict
NCT05887882, a Phase 1 study of Pediatric Brain Tumor and Pediatric Neoplasm, is actively recruiting participants, sponsored by Sabine Mueller, MD, PhD.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 8
- Study locations
Study Summary
This phase I trial tests the safety, side effects, and best dose of ex vivo expanded natural killer cells in treating patients with cancerous (malignant) tumors affecting the upper part of the brain (supratentorial) that have come back (recurrent) or that are growing, spreading, or getting worse (progressive). Natural killer (NK) cells are immune cells that recognize and get rid of abnormal cells in the body, including tumor cells and cells infected by viruses. NK cells have been shown to kill different types of cancer, including brain tumors in laboratory settings. Giving NK cells from unrelated donors who are screened for optimal cell qualities and determined to be safe and healthy may be effective in treating supratentorial malignant brain tumors in children and young adults.
Conditions Studied
Interventions
- OTHER Quality-of-Life Assessment
- PROCEDURE Magnetic Resonance Imaging (MRI)
- BIOLOGICAL Universal Donor (UD) Transforming growth factor beta imprinting (TGFβi) Natural Killer (NK) Cells
- PROCEDURE Implantation
Study Locations (8)
Alabama
- University of Alabama Birmingham - Birmingham
California
- University of California, San Francisco - San Francisco
Indiana
- Indiana University - Indianapolis
Maryland
- Johns Hopkins - Baltimore
Missouri
- Washington University in Saint Louis - St Louis
New Jersey
- Hackensack University Medical Center - Hackensack
Ohio
- Nationwide Children's Hospital - Columbus
Washington
- Seattle Children's - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2024-05-31 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05887882
The ClinicalTrials.gov registry entry for NCT05887882 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 42-participant average among 9 other Pediatric Brain Tumor trials with a reported enrollment target (43% lower). The listed sponsor is Sabine Mueller, MD, PhD, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Pediatric Brain Tumor appearing as the primary indexed condition, and to 4 interventions - of which Quality-of-Life Assessment is the first listed.
NCT05887882 reports 8 study locations spanning 8 distinct geographic areas - top geographies include Alabama, California, Indiana.
Frequently Asked Questions
What is clinical trial NCT05887882 about?
NCT05887882 is a clinical study titled "Intra-Tumoral Injections of Natural Killer Cells for Recurrent Malignant Pediatric Brain Tumors". This phase I trial tests the safety, side effects, and best dose of ex vivo expanded natural killer cells in treating patients with cancerous (malignant) tumors affecting the upper part of the brain (supratentorial) that have come back (recurrent) or that are growing, spreading, or getting worse (pr...
What is the current status of trial NCT05887882?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2024-05-31. Estimated completion is 2027-12-31.
What conditions does trial NCT05887882 study?
This clinical trial studies the following conditions: Pediatric Brain Tumor, Pediatric Neoplasm, Recurrent Pediatric Brain Tumor.
What interventions are being tested in trial NCT05887882?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Magnetic Resonance Imaging (MRI) (PROCEDURE), Universal Donor (UD) Transforming growth factor beta imprinting (TGFβi) Natural Killer (NK) Cells (BIOLOGICAL), Implantation (PROCEDURE).
Who is sponsoring clinical trial NCT05887882?
This trial is sponsored by Sabine Mueller, MD, PhD, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05887882 being conducted?
This trial has 8 study locations across Alabama, California, Indiana, Maryland, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pediatric Brain Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i)
RECRUITING · Phase 1
-
GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults
RECRUITING · Phase 1
-
Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas
ACTIVE NOT RECRUITING · Phase 1
-
Survivors Journey+
RECRUITING · NA
-
Feasibility/Acceptability of Attentional-Control Training in Survivors
RECRUITING · NA
-
High-Intensity Interval Exercise in Young Adult Survivors of Pediatric Brain Tumors: A Pilot Feasibility Study
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.